(Q33520386)
Statements
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation (English)
J Thompson Coon
C Green
Z Liu
K Welch
T Moxham
scientific article
No description defined